Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 3
1991 1
1996 5
1997 3
1998 1
1999 2
2000 3
2002 1
2003 1
2004 1
2005 2
2011 2
2012 1
2013 2
2014 2
2016 1
2017 1
2018 1
2019 1
2020 2
2021 1
2022 3
2023 3
2024 5
2025 3
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
Ueno M, Takeda H, Takai A, Morimura H, Nishijima N, Iwamoto S, Okuyama S, Umeda M, Seta T, Ikeda A, Goto T, Miyamoto S, Kayahara T, Uenoyama Y, Matsumura K, Nakano S, Mishima M, Inuzuka T, Eso Y, Takahashi K, Marusawa H, Osaki Y, Hatano E, Seno H. Ueno M, et al. Among authors: morimura h. J Gastroenterol. 2024 Dec;59(12):1107-1118. doi: 10.1007/s00535-024-02150-7. Epub 2024 Sep 18. J Gastroenterol. 2024. PMID: 39289234 Free PMC article.
Lenvatinib Versus Atezolizumab Plus Bevacizumab as First-Line Treatment for Advanced Hepatocellular Carcinoma With a CRAFITY Score of 2: A Multi-Center Retrospective Study.
Ueno M, Takeda H, Takai A, Umeda M, Morimura H, Okuyama S, Nishijima N, Iwamoto S, Nakano S, Nagatomo S, Seta T, Goto T, Ikeda A, Kayahara T, Miyamoto S, Yazumi S, Ueo T, Uenoyama Y, Matsumura K, Mishima M, Inuzuka T, Eso Y, Takahashi K, Marusawa H, Osaki Y, Hatano E, Seno H. Ueno M, et al. Among authors: morimura h. Hepatol Res. 2026 Jan;56(1):100-110. doi: 10.1111/hepr.70040. Epub 2025 Sep 13. Hepatol Res. 2026. PMID: 40944673
Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.
Ueno M, Su YY, Takai A, Huang YH, Morimura H, Nishijima N, Lin SM, Chang CW, Iwamoto S, Nagatomo S, Lai HC, Mitani T, Ikeda A, Uenoyama Y, Umeda M, Chen SC, Chuang CH, Lai SW, Lee TY, Nakano S, Dai CY, Goto T, Su TH, Hsu CS, Lo CC, Takeda H, Osaki Y, Hatano E, Lee PC, Lin PT, Wang HW, Hsu WF, Liu TH, Seno H. Ueno M, et al. Among authors: morimura h. Liver Cancer. 2026 Jun 1. doi: 10.1159/000552808. Online ahead of print. Liver Cancer. 2026. PMID: 42495656 Free PMC article.
Dexmedetomidine is safe and effective for reducing intraprocedural pain in colorectal endoscopic submucosal dissection.
Iwagami H, Akamatsu T, Matsuyama K, Hanawa Y, Tonomura K, Chikugo E, Ogino S, Morimura H, Shimoyama M, Terashita T, Nakano S, Wakita M, Edagawa T, Konishi T, Matsumoto H, Nakatani Y, Urai S, Seta T, Uenoyama Y, Yamashita Y. Iwagami H, et al. Among authors: morimura h. DEN Open. 2023 Mar 27;3(1):e223. doi: 10.1002/deo2.223. eCollection 2023 Apr. DEN Open. 2023. PMID: 36992692 Free PMC article.
54 results